RA CAPITAL MANAGEMENT, L.P.

Position in DSGN — Design Therapeutics, Inc.

CIK 1346824 BOSTON, MA

Position in DSGN

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$31,632,432

+$17,924,679 QoQ

Shares Held

2,972,973

+103.4% QoQ

Ownership

4.75%

of shares outstanding

% of Portfolio

0.34%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2021

13 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

RA CAPITAL MANAGEMENT, L.P. holds $11,082,969,028 across 75 Biotechnology names.

#	Ticker	Company	Shares	Value (USD)
1	ASND	Ascendis Pharma A/S	10,281,496	$2,742,280,613
2	PBLS	Parabilis Medicines, Inc.	28,933,371	$791,906,364
3	RYTM	Rhythm Pharmaceuticals, Inc.	6,666,837	$740,218,912
4	PCVX	Vaxcyte, Inc.	11,474,599	$667,018,439
5	SION	Sionna Therapeutics, Inc.	9,905,045	$435,722,929
6	TYRA	Tyra Biosciences, Inc.	12,198,625	$389,624,082
7	EWTX	Edgewise Therapeutics, Inc.	8,392,730	$340,996,619
8	NAMS	NewAmsterdam Pharma Co N.V.	9,883,524	$330,779,298

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$31,632,432	2,972,973	+103.4%	Shares	Sole	2026-05-15
2025-12-31	$13,707,753	1,461,381	+207.2%	Shares	Sole	2026-02-17
2025-09-30	$3,582,013	475,699	-84.0%	Shares	Sole	2025-11-14
2023-06-30	$18,718,755	2,971,231	0.0%	Shares	Sole	2023-08-14
2023-03-31	$17,144,002	2,971,231	0.0%	Shares	Sole	2023-05-15
2022-12-31	$30,484,830	2,971,231	+7.1%	Shares	Sole	2023-02-14
2022-09-30	$46,368,422	2,773,231	+26.8%	Shares	Sole	2022-11-14
2022-06-30	$30,612,904	2,186,636	0.0%	Shares	Sole	2022-08-15
2022-03-31	$35,314,171	2,186,636	0.0%	Shares	Sole	2022-05-16
2021-12-31	$46,815,876	2,186,636	0.0%	Shares	Sole	2022-02-14
2021-09-30	$32,121,682	2,186,636	0.0%	Shares	Sole	2021-11-15
2021-06-30	$43,492,190	2,186,636	0.0%	Shares	Sole	2021-08-16
2021-03-31	$65,380,416	2,186,636	—	Shares	Sole	2021-05-17
No filing history on record for this holder in this stock.